Rigel Pharmaceuticals has entered into an asset purchase agreement with Blueprint Medicines to purchase certain assets related to the drug pralsetinib for $15 million, with potential milestone and royalty payments in the future.
AI Assistant
RIGEL PHARMACEUTICALS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.